Short answer
Evolus, Inc. (EOLS) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $78M (up 13.0% year over year) with net income of −$13M.
Q3 2026 key financials · XBRL
- Revenue
- $78M
- +13.0% YoY · −7.3% QoQ
- Net income
- −$13M
- +20.5% YoY · −55.4% QoQ
- Operating margin
- -10.8%
- Gross margin
- 65.0%
- EPS (diluted)
- −$0.19
- +20.8% YoY · −46.2% QoQ
Source: XBRL data from the Evolus, Inc. (EOLS) Q3 2026 10-Q on SEC EDGAR. USD.
Evolus, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $78.0M, up 13.0% from $69.0M, driven by higher Jeuveau and Evolysse sales
- Gross margin 65.0% vs 66.5% YoY, operating loss $8.4M vs $11.5M
- One reportable segment, Jeuveau and Evolysse; both products cited as revenue-growth drivers
- Cash $41.7M, operating cash use $15.5M through nine months vs $55.1M YoY
- Outlook: growth dependent on Evolysse launches and U.S. approvals, with tariff and discretionary-spending headwinds
Risk Factors
- New tariff risk triggered by 2026 Section 232 action: South Korean Jeuveau imports currently face 15% tariffs, with potential rates up to 100%
- Regulatory risk from Section 232 medical-device investigation: future tariffs, quotas, or import restrictions could affect France-sourced Evolysse
- Competitive risk: AbbVie and Galderma retain larger market shares, sales forces, portfolios, and discounting capacity
- Financial risk: $31.2 million nine-month net loss and $692.3 million accumulated deficit increase reliance on future financing
- Supply risk: sole reliance on Daewoong and Symatese leaves Jeuveau and Evolysse vulnerable to manufacturing disruptions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Evolus, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.